These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29870408)

  • 1. Ocular Surface Disease in the Glaucoma Patient.
    Banitt M; Jung H
    Int Ophthalmol Clin; 2018; 58(3):23-33. PubMed ID: 29870408
    [No Abstract]   [Full Text] [Related]  

  • 2. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular surface disease in patients with ocular hypertension and glaucoma.
    Stewart WC; Stewart JA; Nelson LA
    Curr Eye Res; 2011 May; 36(5):391-8. PubMed ID: 21501071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glaucoma therapy and ocular surface disease: current literature and recommendations.
    Anwar Z; Wellik SR; Galor A
    Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unilateral drug-induced ocular pseudopemphigoid.
    Gibran SK
    Eye (Lond); 2004 Dec; 18(12):1270. PubMed ID: 15044940
    [No Abstract]   [Full Text] [Related]  

  • 7. Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops.
    Ferreras A; Figus M; Fogagnolo P; Iester M; Frezzotti P
    Curr Med Chem; 2019; 26(22):4223-4224. PubMed ID: 31612807
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-induced cicatrising granulomatous conjunctivitis.
    Kahana A; Marcet MM; Albert DM; Thliveris AT
    Br J Ophthalmol; 2007 May; 91(5):691-2. PubMed ID: 17446509
    [No Abstract]   [Full Text] [Related]  

  • 9. The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension.
    Costa VP; Marcon IM; Galvão Filho RP; Malta RF
    Arq Bras Oftalmol; 2013; 76(4):221-5. PubMed ID: 24061832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
    Potop V
    Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patients.
    Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
    Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
    Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
    Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
    Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
    Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
    J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.